Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results , with sales up 6.8% year on year to $15.62 billion ...

Shares of Merck are sliding in early trading after ... forecast due partly to a pause in shipments of one of its top-selling products to China Shares of Merck slid Tuesday after the drugmaker ...

Founded in 1891, Merck (NYSE:MRK) is a global pharmaceutical company that develops prescription medicines, vaccines, biologic therapies, and animal health products. The branded pharmaceutical ...

Merck 2025 Sales Forecast Underwhelms as ... sales forecast due partly to a pause in shipments of one of its top-selling products to China. The drugmaker plans to temporarily pause shipments ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.